Homology Medicines, Inc. (FIXX) financial statements (2022 and earlier)

Company profile

Business Address ONE PATRIOTS PARK
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments155,873187,551213,293188,649217,431178,003206,643
Cash and cash equivalents108,38295,829116,313104,416217,431178,003167,636
Short-term investments47,49191,72296,98084,233  39,007
Other undisclosed current assets36,0364,2664,6443,0032,1333,2523,164
Total current assets:191,909191,817217,937191,652219,564181,255209,807
Noncurrent Assets
Operating lease, right-of-use asset15,6075,0285,3285,6185,8976,1496,386
Property, plant and equipment2,25232,69734,37936,15337,00239,68440,771
Other undisclosed noncurrent assets1,9531,2741,2741,2741,2741,2741,274
Total noncurrent assets:19,81238,99940,98143,04544,17347,10748,431
TOTAL ASSETS:211,721230,816258,918234,697263,737228,362258,238
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,57911,00411,5279,02912,1199,72912,071
Accounts payable2,3663,5225,6964,8784,7223,3167,103
Accrued liabilities1,408798577830495772656
Employee-related liabilities7,8056,6845,2543,3216,9025,6414,312
Deferred revenue3,2083,2084,0075,1845,6322,939774
Other undisclosed current liabilities2,4394,4934,0003,5954,9074,5106,719
Total current liabilities:17,22618,70519,53417,80822,65817,17819,564
Noncurrent Liabilities
Long-term debt and lease obligation23,68811,58212,04712,49812,94113,54014,190
Operating lease, liability23,68811,58212,04712,49812,94113,54014,190
Liabilities, other than long-term debt1,1561,9582,7603,56232,14327,42229,780
Deferred revenue1,1561,9582,7603,56232,14327,42229,780
Total noncurrent liabilities:24,84413,54014,80716,06045,08440,96243,970
Total liabilities:42,07032,24534,34133,86867,74258,14063,534
Stockholders' equity
Stockholders' equity attributable to parent169,651198,571224,577200,829195,995170,222194,704
Common stock6665544
Additional paid in capital593,784589,119584,510530,288524,358468,795465,034
Accumulated other comprehensive income (loss)(7)(5)2(23)  11
Accumulated deficit(424,132)(390,549)(359,941)(329,441)(328,368)(298,577)(270,345)
Total stockholders' equity:169,651198,571224,577200,829195,995170,222194,704
TOTAL LIABILITIES AND EQUITY:211,721230,816258,918234,697263,737228,362258,238

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues8021,6772,18729,305980567567
Sublease income   235228  
Gross profit:8021,6772,18729,305980567567
Operating expenses(34,427)(32,338)(32,739)(30,416)(30,782)(28,840)(36,264)
Operating loss:(33,625)(30,661)(30,552)(1,111)(29,802)(28,273)(35,697)
Nonoperating income845352762241357
Investment income, nonoperating42  3811  
Other nonoperating income425352381141357
Loss before gain (loss) on sale of properties:(33,541)(30,608)(30,500)(1,035)(29,780)(28,232)(35,340)
Other undisclosed net loss(42)  (38)(11)  
Net loss available to common stockholders, diluted:(33,583)(30,608)(30,500)(1,073)(29,791)(28,232)(35,340)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(33,583)(30,608)(30,500)(1,073)(29,791)(28,232)(35,340)
Comprehensive loss:(33,583)(30,608)(30,500)(1,073)(29,791)(28,232)(35,340)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)(7)25(23) (11)30
Comprehensive loss, net of tax, attributable to parent:(33,585)(30,615)(30,475)(1,096)(29,791)(28,243)(35,310)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: